Updated on 22 January 2015
What are the industry looking forward to, in the new year?
Singapore: Frost & Sullivan forecasts that the global branded pharma and biotech industry will generate nearly $1.1 trillion revenue in 2015 and Asia would experience a favorable period with innovations in biotech sector and flourish of generics companies due to patent expiry. Personalized medicine and emergence of new therapies in areas such as regenerative medicine and preventive healthcare will be major focus areas for stakeholders. Technology, innovation, public policy, and market strategies together will play a key role in driving the year ahead.
Mr David Utama, president & CEO, GE Healthcare ASEAN
"Our legacy as a leader of big iron innovation was enhanced by new products in MR and CT this past year, with solutions aimed at lowering dose, enhancing image quality to boost clinical confidence and helping clinicians deliver more efficient and personalized care with diagnostic accuracy. As we look forward, the world of healthcare is becoming more reliant on technology and data to save clinicians time through efficient workflows, increased data sharing, and analytics. We're looking at providing new solutions that address clinicians' need for speed, improved image clarity, connectivity and data availability. These software advancements provide tools to help clinicians improve speed of service and quality of care for patients. With these latest innovations, doctors can move around more freely, allowing them to be more nimble and get to a diagnosis quickly.
Machines are evolving year on year, but next year's spotlight is expected to continue shifting towards software and new ways to improve practice. With the advent of Cloud Imaging and Big Data, the vast potential of the reams of patient information now available to clinicians is only just being explored. Some say the next step in our medical evolution will come in the form of big data and personalized medicine. The ubiquity of information technology has left us with an untapped wealth of patient data that is now being used to streamline health services."
Mr Simon Angeldorff, CEO, Envirotainer
"In 2015, we see increasing interest in security, quality assured training schemes (like Envirotainer's QEP program), and continuous data monitoring. Pharmaceutical companies demand a higher level of service and pro-activity from all suppliers, which is a challenge we embrace.
Our solutions are still breaking new barriers across the globe. In new markets, the trade, customs and aviation policies are not always transparent for all stake-holders, which could limit supply. We see strong international initiatives like the EU GDP as important pillars on which a more transparent way of working with the cold chain can be developed, for pharmaceutical companies, forwarders, airlines and solution providers such as Envirotainer.
Our customers have always asked for flexibility and capacity to serve a market where needs can fluctuate from one week to another and we see that need increasing for each year. For us to be able to meet that need, we've invested to substantially increase our fleet size enabling capacity to support larger volumes also over shorter peak periods.
Initiatives among policy makers to align guidelines across the globe are highly appreciated and serves the whole industry to align SOPs, and adopt all parts of the cold chain solution in order to even further secure the integrity of the products."